Become A Featured Company

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

Ryan Allway

December 2nd, 2020

Psychedelics

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has amended its sponsored research agreement with University Health Network (“UHN”) for the development of panaceAI™, the Company’s drug repurposing platform, to also include the development of a digital therapeutics platform to combine with potential psychedelic therapies, including the Company’s ketamine and psilocybin focused product pipeline for disorders of the brain and nervous system.

The development work for the Company’s digital therapeutics platform will be conducted by a dedicated research team at Diamandis Lab, which is led by Dr. Phedias Diamandis, MD, PhD, FRCPC, the Principal Investigator who is also advancing the Company’s research with panaceAI™ by merging big data and artificial intelligence to accelerate the drug discovery process.

“We are committed to advancing the clinical development of our product pipeline with ketamine and psilocybin while also speeding up the process of finding effective uses of psychedelic-derived medicines with panaceAI™ and complementing them with a digital therapeutic platform to be synergistic with our focus on psychedelic pharmaceuticals,” said Fabio Chianelli, CEO of PharmaTher. “Dr. Diamandis and his research team at UHN, having a rich research program focused on applying artificial intelligence and machine learning to brain disease, are a perfect fit for guiding our digital therapeutics objectives for neurological disorders, such as Parkinson’s disease, depression, neuropathic pain, traumatic brain injury and stroke.”

The global digital therapeutics market was valued at US$ 2.69 billion in 2019 and is expected to reach US$ 11.82 billion by 2027.1 According to the Digital Therapeutics Alliance, digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. Digital therapeutics products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. They are reviewed and cleared or approved by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use.   Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.2

“We are excited to evolve our relationship with PharmaTher for the development and commercialization of a digital therapeutics solution for psychedelic medicines in the treatment of neurological disorders,” said Dr. Diamandis. “My lab has been focused on developing artificial intelligence and machine learning tools directed with the goal of leveraging innovation in technology and digital solutions to address unmet medical needs. Digital therapeutic platforms that can continuously document patients’ biology and symptomatology offer many unique benefits. These include the ability to personalize medication regimens using information gathered both from the individual and big data from large number of patients. The amount of data and feedback you can collect and provide with digital technologies is unprecedented. We are excited to apply these principles and machine learning tools we are developing in the lab for patients with a wide variety of neurological symptoms.”

The research program will be led by Dr. Phedias Diamandis, who is an Assistant Professor at the University of Toronto, a Neuropathologist at UHN and a Scientist at Princess Margaret Cancer Centre. His research team focuses on applying innovations in artificial intelligence, big data, tissue bioengineering and large-scale drug profiling, to understand and develop new therapeutic strategies for a wide variety of neurological disorders.

Under the agreement, a dedicated team is directed to develop a digital therapeutic platform integrating self-monitoring applications and machine learning to monitor responses and benefits of psychedelic compounds to treat neurological disorders.

Psychedelics, such as psilocybin act on the serotonin (5-hydroxytryptamine; 5-HT) 2A receptor and have gained clinical interest as potential therapeutic solutions to address difficult to treat neuropsychiatric disorders such as depression, posttraumatic Stress Disorder (“PTSD”) and addiction. The US Food and Drug Administration (“FDA”) designated both MDMA-assisted psychotherapy for PTSD and psilocybin for treatment-resistant depression as ‘breakthrough therapies’. Non-profit institutions such as Multidisciplinary Association for Psychedelic Studies (“MAPS”), Usona Institute and the Heffter Research Institute as well as academia institutes with dedicated psychedelic and consciousness research centres such as Johns Hopkins University and Imperial College London are also currently focused on the development and clinical research of psychedelic-derived medicines.

About PharmaTher Inc.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. PharmaTher repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our goal is to advance the commercialization of panaceAI™, our drug repurposing artificial intelligence platform, and our ketamine focused product pipeline in the treatment of Parkinson’s Disease, depression, and pain. Learn more at:  PharmaTher.com and follow us on Facebook, Twitter and LinkedIn.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading